Preparation, characterization, and pharmacokinetics of rivaroxaban cocrystals with enhanced in vitro and in vivo properties in beagle dogs

• Egile Nagusiak: Yuanyuan Meng (Egilea), Fangyun Tan (Egilea), Jiaxin Yao (Egilea), Yanan Cui (Egilea), Yumiao Feng (Egilea), Zhiping Li (Egilea), Yuli Wang (Egilea), Yang Yang (Egilea), Wei Gong (Egilea), Meiyan Yang (Egilea), Xiaolong Kong (Egilea), Chunsheng Gao (Egilea)
• Formatua: Liburua
• Argitaratua: Elsevier, 2022-12-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Rivaroxaban (RIV) is a direct Factor Xa inhibitor anticoagulant, but the oral bioavailability of RIV is estimated to be only 60% due to its poor solubility. The aim of the present study was to improve the solubility and bioavailability of RIV. Five cocrystals-p-hydroxybenzoic acid (HBA), 2,4-dihydro...